Get started
Author

Shinji Atagi

Observed name: S. Atagi
OpenAlex ID: A5059659803
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial
2024 · Kazuma Sakura, Muneyoshi Kuroyama, et al. · Cancer Immunology Immunotherapy · 6
PDF
P1.14-19 Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma
2018 · K. Sakura, C. Lee, et al. · Journal of Thoracic Oncology · 2
PDF
64P Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan
2022 · M. Shimokawa, M. Kanazu, et al. · Annals of Oncology
PDF
Clinical study of hemagglutinating virus of Japan envelope against chemotherapy resistant pleural mesothelioma
2017 · Shinji Atagi · Immunotherapy Open Access
Serum biomarker analysis of WJOG4107: A randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC).
2014 · Tetsuya Mitsudomi, Yasuo Iwamoto, et al. · Journal of Clinical Oncology
Works count: 6
Citation count: 2,286
H-index: 2
I10-index: 1
Year
Topic
Type